Vera Therapeutics, Inc (VERA) FinancialsVERAFinancialVera Therapeutics, Inc

Evaluating the bottom line, Vera Therapeutics, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -91.75%, provide a clear picture of how effectively VERA converts its operational activities into shareholder value.

In the context of the broader market, VERA competes directly with industry leaders such as PHVS and PGEN. With a market capitalization of $2.65B, it holds a leading position in the sector. When comparing efficiency, VERA's gross margin of N/A stands against PHVS's N/A and PGEN's 94.90%. Such benchmarking helps identify whether Vera Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

Vera Therapeutics has shown a 51.22% increase in stock price over the past year, despite a year-to-date decline of 29.68%. The company has a current ratio of 10.92, indicating strong short-term liquidity, but it has been reporting significant net losses, with the latest quarterly net income at -121.03 million USD.